The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuddihy, Grace, Wasan, Ellen K., Di, Yunyun, Wasan, Kishor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470859/
https://www.ncbi.nlm.nih.gov/pubmed/30813569
http://dx.doi.org/10.3390/pharmaceutics11030099
_version_ 1783411893570895872
author Cuddihy, Grace
Wasan, Ellen K.
Di, Yunyun
Wasan, Kishor M.
author_facet Cuddihy, Grace
Wasan, Ellen K.
Di, Yunyun
Wasan, Kishor M.
author_sort Cuddihy, Grace
collection PubMed
description Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has been very challenging to develop a bioavailable formulation of amphotericin B due to its physical chemical properties, limited water and lipid solubility, and poor absorption. This perspective reviews several novel oral Amphotericin B formulations under development that are attempting to overcome these limitations.
format Online
Article
Text
id pubmed-6470859
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64708592019-04-27 The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized? Cuddihy, Grace Wasan, Ellen K. Di, Yunyun Wasan, Kishor M. Pharmaceutics Perspective Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has been very challenging to develop a bioavailable formulation of amphotericin B due to its physical chemical properties, limited water and lipid solubility, and poor absorption. This perspective reviews several novel oral Amphotericin B formulations under development that are attempting to overcome these limitations. MDPI 2019-02-26 /pmc/articles/PMC6470859/ /pubmed/30813569 http://dx.doi.org/10.3390/pharmaceutics11030099 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Cuddihy, Grace
Wasan, Ellen K.
Di, Yunyun
Wasan, Kishor M.
The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_full The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_fullStr The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_full_unstemmed The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_short The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_sort development of oral amphotericin b to treat systemic fungal and parasitic infections: has the myth been finally realized?
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470859/
https://www.ncbi.nlm.nih.gov/pubmed/30813569
http://dx.doi.org/10.3390/pharmaceutics11030099
work_keys_str_mv AT cuddihygrace thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT wasanellenk thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT diyunyun thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT wasankishorm thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT cuddihygrace developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT wasanellenk developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT diyunyun developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT wasankishorm developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized

Ejemplares similares